merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>The primary reason for skepticism is that the benefit of Kisunla is modest and may not be noticeable to patients or families, and the risks outweigh the potential benefits.</answer>

<question_number>2</question_number>
<answer>The article suggests that the focus on anti-amyloid drugs might discourage patients from participating in trials for other treatments that could be better.</answer>

<question_number>3</question_number>
<answer>Dr. Greicius states that there's no correlation between the removal of amyloid plaques and the clinical response in individual subjects.</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>The higher price of Kisunla is justified because patients can stop the drug after their amyloid plaques are cleared, potentially reducing overall cost and inconvenience.</answer>

<question_number>6</question_number>
<answer>The article suggests that the emphasis on anti-amyloid drugs like Kisunla might discourage patients from participating in trials for other treatments.</answer>

<question_number>7</question_number>
<answer>Kisunla can potentially reduce the inconvenience of treatment because patients can stop the drug after their amyloid plaques are cleared.</answer>

<question_number>8</question_number>
<answer>amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>The factor is the level of tau protein; patients with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>